Clinical Trial

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Name: Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer — clinical trial record (NCT06050317)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2023-09-21; most recent amendment 2026-04-27.

Trial Details

NCT Number	NCT06050317
Lead Sponsor	Shandong Cancer Hospital and Institute
Conditions	Pancreas Cancer
Enrollment	25 participants
Start Date	2023-08-18
Primary Completion	2025-08-18 (estimated)
Study Completion	2026-08-18 (estimated)
Updated on ClinicalTrials.gov	2026-05-01